Join the club for FREE to access the whole archive and other member benefits.

Ann Belien

Founder and CEO of Rejuvenate Biomed

Ann Beliën is the founder and CEO of Rejuvenate Biomed. Rejuvenate Biomed studies the biology of aging and is repurposing prescription drugs with the aim to delay the onset of multiple age-related diseases. One of the portfolio products is focusing on sarcopenia as an entry into the space of healthy aging. Ann has over 17 years of experience in drug development from bench to market, which she acquired at Johnson & Johnson throughout multiple international assignments (US, NL, BE).  She joined Johnson & Johnson in 2000, after a postdoc at ETH, Zürich, Switzerland. She holds a PhD from the University of Irchel, Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.

Visit website: https://www.rejuvenatebiomed.com/en/our-team/ann-belien

 ann-belien-phd-1721125

See also: Company Rejuvenate Biomed - Biomedical company researching the biology of aging and developing drugs for age related diseases.

Details last updated 03-Mar-2021

Ann Belien is also referenced in the following:

Global Healthspan Summit 2023

29-Nov-2023 to 30-Nov-2023

Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)

Rejuveron Age Better Live Longer Symposium

10-May-2022

Symposium about healthy living organized by Rejuveron (FREE)

Ann Belien News

Rejuvenate Biomed's potential drug candidate combats sarcopenia in older adults

Rejuvenate Biomed - 21-Feb-2024

Phase 1b trial shows RJx-01's ability to improve muscle strength, function, and fatigue resistance

Read more...

Rejuvenate Biomed raises 3.2 million euros for anti-ageing drugs

PharmiWeb.com - 02-Mar-2021

Accelerates clinical trial plans for its lead candidate Rlx-01 targeting age-related muscle failure

Read more...